SlideShare une entreprise Scribd logo
1  sur  34
Methodology for estimating the wider economic impacts of
health treatments
1. Changes in patient health have wider economic consequences
2. Patients’ wider economic impact: production net of consumption
3. Estimating net production as a function of patient health
4. Results – single patient net production rates (given health state)
Patient
Age: 64
Gen: M
(ICD:
QoL:
G)
60%
Net production
£500 pcm
Calculation
Mechanism
5. Results – treatment impacts (by ICD, and for marginal NHS £)
Methodology for estimating the wider economic impacts of
health treatments
1. Changes in patient health have wider economic consequences
2. Patients’ wider economic impact: production net of consumption
3. Estimating net production as a function of patient health
4. Results – single patient net production rates (given health state)
Patient
Age: 64
Gen: M
(ICD:
QoL:
G)
60%
Net production
£500 pcm
Calculation
Mechanism
5. Results – treatment impacts (by ICD, and for marginal NHS £)
Measuring the economic impact of health using net production
Health (and treatments) have impacts beyond the patient
Health
(QALYs)
Work more?
Pay more tax?
Need less benefits?
Costs
(£)
Need less social care?
Need less care by family?
Economic impact
on society
(i.e. other people)
Contribute to family finances?
Look after others?
+
1. Changes in patient health have wider economic consequences
2. Patients’ wider economic impact: production net of consumption
3. Estimating net production as a function of patient health
4. Results – single patient net production rates (given health state)
Patient
Age: 64
Gen: M
(ICD:
QoL:
G)
60%
Net production
£500 pcm
Calculation
Mechanism
5. Results – treatment impacts (by ICD, and for marginal NHS £)
Methodology for estimating the wider economic impacts of
health treatments
Patient Effect on others
Family and
friends
Other
members of
society
Gross production,
or contribution of
resources (+)
Gross consumption,
or utilisation of
resources (-)
Net production
+£500pcm
+£1,500 pcm
-£1,000 pcm
Costs, eg spending on
nursing home
Family income
Domestic work
Need for informal care
by family
Govt costs, eg welfare,
social care
Govt tax revenues
Volunteer work
Any excess production (consumption) by patient means a benefit (cost) to someone else
=£500
pcm
Defining production and consumption effects
Net production = consumption for others
Defining production and consumption effects
Net production = consumption for others
Patient
Family and
friends
Other
members of
society
Gross production,
or contribution of
resources (+)
Gross consumption,
or utilisation of
resources (-)
+£1,500 pcm
-£1,000 pcm
Costs, eg spending on
nursing home
Family income
Domestic work
Need for informal care
by family
Govt costs, eg welfare,
social care
Govt tax revenues
Volunteer work
Any excess production (consumption) by patient means a benefit (cost) to someone else
=£500
pcm
Net production
+£500pcm
1. Changes in patient health have wider economic consequences
2. Patients’ wider economic impact: production net of consumption
3. Estimating net production as a function of patient health
4. Results – single patient net production rates (given health state)
Patient
Age: 64
Gen: M
(ICD:
QoL:
G)
60%
Net production
£500 pcm
Calculation
Mechanism
5. Results – treatment impacts (by ICD, and for marginal NHS £)
Methodology for estimating the wider economic impacts of
health treatments
Illustrative
figures,
pcm
Gross production:
 paid labour
 unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production
£1,500
= £500 pcm
£1,000
Age: 64
Gen: M
ICD:
QoL:
G
60%
- £1,000
£1,500
International Classification of Disease (Chapter-level)
£600
£900
£80
£70
£420
£300
£130
Estimating production and consumption effects
Mechanism estimates production / cons as a function of health
Illustrative
figures,
pcm
Gross production:
 paid labour
 unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production
£1,500
= £500 pcm
£1,000
Age: 64
Gen: M
ICD:
QoL:
G
60%
- £1,000
£1,500
£600
£900
£80
£70
£420
£300
£130
Estimating production and consumption effects
Compare to production with treatment to give impact
 paid labour
 unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production
£1,500
= £500 pcm
£1,000
Age: 64
Gen: M
ICD:
QoL:
G
60%
- £1,000
£1,500
£1,600
= £700 pcm
£900
80%
- £900
£1,600
Raising this patient’s QoL from 60% to 80% generates £200pcm in net production
Treatment
improves QoL by
20%
£600
£900
£80
£70
£420
£300
£130
£950
£30
£20
£420
£300
£130
Gross production:
£650
Estimating production and consumption effects
Compare to production with treatment to give impact
Illustrative
figures,
pcm
Estimating production and consumption effects
Estimating elements as functions of AGIQ – eg paid labour
 paid labour
Patient
Age: 64
Gen: M
ICD:
QoL:
G
80%
 unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Net
production
£1,500
= £500 pcm
£1,000
- £1,000
£1,500
£1,600
= £700 pcm
£900
- £900
£1,600
£900
£80
£70
£420
£300
£130
£950
£30
£20
£420
£300
£130
Gross production:
Illustrative
figures,
pcm£650
Estimating production and consumption effects
Estimating elements as functions of AGIQ – eg paid labour
 paid labour
Patient
Age: 64
Gen: M
ICD:
QoL:
G
80%
£650
Understanding Society
• “did you do paid work
last week?”
• SF16 health instrument
• age, gender etc
ScHARR model
• Map SF16 to EQ5D
(QoL)
• Estimate prob of
doing work as f(Age,
QoL)
ONS wages data
• Monthly wage, by
Age, Gender if in
work
-> £ paid labour pcm = f (Age, Gender, QoL)
+
Estimating production and consumption effects
Main current data sources
Paid labour
Unpaid labour
Formal care
Informal care
Personal paid
consumption
Personal unpaid
consumption
Government
services
AGQ
AGQ
A(I)Q
AGIQ
A
(const)
A
Element Dependent
variables
Main data sources
Annual Survey of Hours and Earnings (AG)
Understanding Society (AQ)
Time Use Survey (AG)
Sick rate, derived from Understanding Soc. (Q)
Adult Soc. Care Survey, GP Patient Survey, PSSRU
data
HoDAR
Living Costs and Food Survey
Time Use Survey
Public Expenditure Statistical Analysis
1. Changes in patient health have wider economic consequences
2. Patients’ wider economic impact: production net of consumption
3. Estimating net production as a function of patient health
4. Results – single patient net production rates (given health state)
Patient
Age: 64
Gen: M
(ICD:
QoL:
G)
60%
Net production
£500 pcm
Calculation
Mechanism
5. Results – treatment impacts (by ICD, and for marginal NHS £)
Methodology for estimating the wider economic impacts of
health treatments
Results – paid production
£pcm paid production as a function of age and QoL
NB this is the rate in a given state – not a treatment impact
QoL
-500
0
500
1,000
1,500
2,000
2,500
10 20 30 40 50 60 70 80 90 100
Age
0
0.2
0.5
0.7
0.9
1.0
paid labour
 unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production (or
consumption)
Age: 64
Gen: M
ICD:
QoL:
G
60%80%
Gross production:
Results – unpaid production
£pcm as a function of age and QoL
QoL
NB this is the rate in a given state – not a treatment impact
0
500
1,000
1,500
2,000
2,500
10 20 30 40 50 60 70 80 90 100
Age
0
0.2
0.5
0.7
0.9
1.0
 paid labour
unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production (or
consumption)
Age: 64
Gen: M
ICD:
QoL:
G
60%80%
Gross production:
Results – unpaid production – general unpaid labour
Hours pcm in full health
• Data from Time Use Survey
• Diaries identify activity for each 10 min interval
0
50
100
150
200
250
300
350
0 10 20 30 40 50 60 70 80 90 100
Age
M - obs
F - obs
M -pred
F - pred
• ~3000 activities classified according to whether represent unpaid labour
 paid labour
unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production (or
consumption)
Age: 64
Gen: M
ICD:
QoL:
G
60%80%
Gross production:
Results – informal care consumption
£pcm as a function of age and QoL
QoL
NB this is the rate in a given state – not a treatment impact
0
500
1,000
1,500
2,000
2,500
10 20 30 40 50 60 70 80 90 100
Age
0
0.2
0.5
0.7
0.9
1.0
 paid labour
 unpaid labour
Gross consumption:
 formal care
informal care
 personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production (or
consumption)
Age: 64
Gen: M
ICD:
QoL:
G
60%80%
Gross production:
Results – formal care consumption
£pcm as a function of age and QoL
QoL
NB this is the rate in a given state – not a treatment impact
 paid labour
 unpaid labour
Gross consumption:
formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production (or
consumption)
Age: 64
Gen: M
ICD:
QoL:
G
60%80%
Gross production:
Results – private paid consumption
£pcm as a function of age and QoL
QoL
NB this is the rate in a given state – not a treatment impact
0
200
400
600
800
1,000
1,200
1,400
10 20 30 40 50 60 70 80 90 100
Age
0
0.2
0.5
0.7
0.9
1.0
 paid labour
 unpaid labour
Gross consumption:
 formal care
 informal care
personal paid cons.
 personal unpaid cons.
 government services
Patient
Net
production (or
consumption)
Age: 64
Gen: M
ICD:
QoL:
G
60%80%
Gross production:
Results – private unpaid consumption
£pcm as a function of age and QoL
QoL
NB this is the rate in a given state – not a treatment impact
 paid labour
 unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
personal unpaid cons.
 government services
Patient
Net
production (or
consumption)
Age: 64
Gen: M
ICD:
QoL:
G
60%80%
Gross production:
Results – Government consumption
£pcm as a function of age and QoL
QoL
NB this is the rate in a given state – not a treatment impact
0
100
200
300
400
500
600
10 20 30 40 50 60 70 80 90 100
Age
0
0.2
0.5
0.7
0.9
1.0
 paid labour
 unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
government services
Patient
Net
production (or
consumption)
Age: 64
Gen: M
ICD:
QoL:
G
60%80%
Gross production:
Results – TOTAL NET PRODUCTION
£pcm as a function of age and QoL
QoL
NB this is the rate in a given state – not a treatment impact
-5,000
-4,000
-3,000
-2,000
-1,000
0
1,000
2,000
10 20 30 40 50 60 70 80 90 100
Age
0
0.2
0.5
0.7
0.9
1.0
 paid labour
Patient
Age: 64
Gen: M
ICD:
QoL:
G
80%
 unpaid labour
Gross consumption:
 formal care
 informal care
 personal paid cons.
 personal unpaid cons.
 government services
Net
production (or
consumption)
Gross production:
1. Changes in patient health have wider economic consequences
2. Patients’ wider economic impact: production net of consumption
3. Estimating net production as a function of patient health
4. Results – single patient net production rates (given health state)
Patient
Age: 64
Gen: M
(ICD:
QoL:
G)
60%
Net production
£500 pcm
Calculation
Mechanism
5. Results – treatment impacts (by ICD, and for marginal NHS £)
Methodology for estimating the wider economic impacts of
health treatments
Calculating net production effects of health treatments
Principle: aggregate over time, like QoL (for QALYs)
QoL
Net
prod
(pa)
QALY gain
£1,000 + £2,000
1 2
Time, yrs
0.5
1.0
= 1.5 QALY
untreated
treated
1 2
Time, yrs
£2,000
untreated
treated
£1,000 = £3,000
0.5 + 1
Net production impact
In principle straightforward – map directly from QoL
Calculating net production effects of health treatments
Practical problem: net production non-linear, esp. over age
-5,000
-4,000
-3,000
-2,000
-1,000
0
1,000
2,000
10 20 30 40 50 60 70 80 90 100
Age
0
0.2
0.5
0.7
0.9
1.0
• Cannot use average patient ages
• Need to calculate across actual ages for affected population..
• ..or use reference estimates representing population age distribution
Reference Estimates (1281 ICDs)
ICD
-eg M06:
Rheumatoid
Arthritis
For each ICD: distrib. of patients (16 AG bins)
= £37,745
per QALY gained
£ net
production
+ enough data for each bin to calculate
all elements of net production
0%
5%
10%
15%
20%
25%
30%
35%
40%
0-4 5-14 15-29 30-44 45-59 60-69 70-79 80+
Patient population distribution
F
M
Age bins
Calculating net production effects of health treatments
One solution: use reference estimates
= £2.52
per £NHS*
* Assuming £15,000
marginal cost / QALY
Production and consumption effects of health treatments
M06 Rheumatoid arthritis: results by category, and key inputs
0%
5%
10%
15%
20%
25%
30%
35%
40%
0-4 5-14 15-29 30-44 45-59 60-69 70-79 80+
Patient population distribution
F
M
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0-4 5-14 15-29 30-44 45-59 60-69 70-79 80+
Distribution of QALY gain by QoL vs LoL
QoL
LoL
Total QoL gains LoL gains
Total production, £ 26,849 25,691 1,158
Paid production, £ 11,276 11,008 268
Unpaid production, £ 15,573 14,683 890
Total consumption, £ -10,896 -14,601 3,705
Formal care, £ -1,765 -2,293 528
Informal care, £ -13,157 -13,509 352
Private paid consumption, £ 1,492 489 1,003
Private unpaid consumption, £ 1,946 712 1,234
(Childcare consumption), £ 0 0 0
Govt consumption, £ 588 0 588
Net production (prod - cons), £ 37,745 40,292 -2,547
Production and consumption effects of health treatments
M06 Rheumatoid arthritis: paid labour impact
Production and consumption effects of health treatments
M06 Rheumatoid arthritis: informal care impact
0
2
4
6
8
10
12
14
0-4 5-14 15-29 30-44 45-59 60-69 70-79 80+ Ave
Informal care need pp, days pcm
Untreated
Treated
Results: net production impact of NHS treatments
Net production impact in select conditions
Code Disease £NP / QALY £NP / £NHS
F03 Dementia 40,068 2.67
M05 Rheumatoid arthritis 37,745 2.52
E11 Diabetes 30,969 2.06
M81 Osteoporosis 23,483 1.57
F30 Depression 22,826 1.52
F20 Schizophrenia 19,625 1.31
G20 Parkinson's disease 16,950 1.13
J45 Asthma 16,267 1.08
G40 Epilepsy 16,031 1.07
displ (average displaced QALY) 13,925 0.93
C53 Cervical cancer 11,248 0.75
E66 Obesity 8,524 0.57
C50 Breast cancer 8,072 0.54
I64 Stroke -1,350 -0.09
C18 Colon cancer -2,262 -0.15
I21 Acute myocardial infarction -8,223 -0.55
I26 Embolisms, fibrillation, thrombosis -10,705 -0.71
J10 Influenza -14,982 -1.00
C22 Liver cancer -25,867 -1.72
C34 Lung cancer -29,135 -1.94
C25 Pancreatic cancer -46,141 -3.08
Results: net production impact of NHS treatments
Description of NHS activity at the margin
16 A/G groups
F 0-5
F 6-15
F 16-30
F 31-45
F 46-59
F 60-69
F 70-79
F 80+
M 0-5
M 6-15
M 16-30
M 31-45
M 46-59
M 60-69
M 70-79
M 80+
F 0-5
Net prod. / £
-1.27
-1.32
-0.51
1.20
0.55
-0.85
-1.59
-2.31
-1.43
-1.52
-0.59
1.52
0.76
-0.90
-1.63
-2.18
-0.13
0.09
0.72
1.70
1.61
0.24
0.04
-0.01
-0.27
-0.12
0.32
1.83
1.51
-0.08
-0.41
-0.55
-0.15
£1
NHS
(margin) F 0-5
F 6-15
F 16-30
F 31-45
F 46-59
F 60-69
F 70-79
F 80+
M 0-5
M 6-15
M 16-30
M 31-45
M 46-59
M 60-69
M 70-79
M 80+
£
Net
Prod
(margin)
1,281 conditions
Abnormal blood-pressure reading, without diagnosis
Abnormal findings in cerebrospinal fluid
Abnormal findings in specimens from digestive organs & abdominal cavity
Abnormal findings in specimens from male genital organs
Abnormal findings in specimens from other organs, systems and tissues
Abnormal findings in specimens from respiratory organs and thorax
Abnormal findings on antenatal screening of mother
Abnormal findings on diagnostic imaging of breast
Abnormal findings on diagnostic imaging of central nervous system
Abnormal findings on diagnostic imaging of lung
Abnormal findings on diagnostic imaging of other body structures
Abnormal involuntary movements
Abnormal results of function studies
Abnormal serum enzyme levels
Abnormalities of breathing
Abnormalities of forces of labour
Abnormalities of gait and mobility
Abnormalities of heart beat
Abnormality of red blood cells
Abnormality of white blood cells, not elsewhere classified
…
Venous complications in pregnancy
Venous complications in the puerperium
Ventral hernia
Viral agents as the cause of disease classified to other chapters
Viral and other specified intestinal infections
Viral conjunctivitis
Viral infection of unspecified site
Viral meningitis
Viral pneumonia, not elsewhere classified
Viral warts
Visual disturbances
Vitamin A deficiency
Vitamin B12 deficiency anaemia
Vitamin D deficiency
Vitiligo
Voice disturbances
Volume depletion
Whooping cough
Yaws
Zoster [herpes zoster]
Zygomycosis
Results: net production impact of NHS treatments
Net production impact marginal £ spent in NHS
Net production, £ 0.93
Production, £ 1.51
Paid production, £ 0.63
Unpaid production, £ 0.89
Consumption, £ 0.59
Formal care consumption, £ -0.02
Informal care consumption, £ -0.17
Private paid consumption, £ 0.29
Private unpaid consumption, £ 0.34
Childcare consumption, £ 0.00
Government consumption, £ 0.14
Direct GDP impact
Impact on
informal carers
Total economic value
Total production
impact
£1
NHS
(margin)
NB this is additional to value of health itself
1. Changes in patient health have wider economic consequences
2. Patients’ wider economic impact: production net of consumption
3. Estimating net production as a function of patient health
4. Results – single patient net production rates (given health state)
Patient
Age: 64
Gen: M
(ICD:
QoL:
G)
60%
Net production
£500 pcm
Calculation
Mechanism
5. Results – treatment impacts (by ICD, and for marginal NHS £)
Methodology for estimating the wider economic impacts of
health treatments

Contenu connexe

Similaire à Wider_economic_impacts_of_health_treatments

Vasco Da Gama 2015 Dublin The Effect of the Economic Crisis on the Irish Heal...
Vasco Da Gama 2015 Dublin The Effect of the Economic Crisis on the Irish Heal...Vasco Da Gama 2015 Dublin The Effect of the Economic Crisis on the Irish Heal...
Vasco Da Gama 2015 Dublin The Effect of the Economic Crisis on the Irish Heal...DrWilliamBehan
 
Budget 2020 summary for workers and business
Budget 2020 summary for workers and businessBudget 2020 summary for workers and business
Budget 2020 summary for workers and businessLaura Comben
 
Richard_Dasher_Healing the Economy_Estimating the Economic Impact of India’s ...
Richard_Dasher_Healing the Economy_Estimating the Economic Impact of India’s ...Richard_Dasher_Healing the Economy_Estimating the Economic Impact of India’s ...
Richard_Dasher_Healing the Economy_Estimating the Economic Impact of India’s ...Dr. Amit Kapoor
 
John Appleby on improving NHS productivity
John Appleby on improving NHS productivityJohn Appleby on improving NHS productivity
John Appleby on improving NHS productivityThe King's Fund
 
Stephen Aldridge -Public sector efficiency in the UK
Stephen Aldridge -Public sector efficiency in the UKStephen Aldridge -Public sector efficiency in the UK
Stephen Aldridge -Public sector efficiency in the UKOECD CFE
 
Earnings-related benefits in Ireland: Rationale, costs and work incentives
 Earnings-related benefits in Ireland: Rationale, costs and work incentives Earnings-related benefits in Ireland: Rationale, costs and work incentives
Earnings-related benefits in Ireland: Rationale, costs and work incentivesEconomic and Social Research Institute
 
Understanding Integrated Care in England
Understanding Integrated Care in EnglandUnderstanding Integrated Care in England
Understanding Integrated Care in EnglandMalachy Rice
 
Estimating the Budgetary Implications of Prevention Policies
Estimating the Budgetary Implications of Prevention PoliciesEstimating the Budgetary Implications of Prevention Policies
Estimating the Budgetary Implications of Prevention PoliciesCongressional Budget Office
 
Chapter 2
Chapter 2Chapter 2
Chapter 2arina
 
Slides NERI Seminar - PGK & TH - 12 Sept 18
Slides NERI Seminar - PGK & TH - 12 Sept 18Slides NERI Seminar - PGK & TH - 12 Sept 18
Slides NERI Seminar - PGK & TH - 12 Sept 18NevinInstitute
 
Assessing Effects on the Federal Budget of Policies to Promote Health and Pre...
Assessing Effects on the Federal Budget of Policies to Promote Health and Pre...Assessing Effects on the Federal Budget of Policies to Promote Health and Pre...
Assessing Effects on the Federal Budget of Policies to Promote Health and Pre...Congressional Budget Office
 
Commissioner Bridget Gainer - Path to Solvency II, Health Care Spend & Pensio...
Commissioner Bridget Gainer - Path to Solvency II, Health Care Spend & Pensio...Commissioner Bridget Gainer - Path to Solvency II, Health Care Spend & Pensio...
Commissioner Bridget Gainer - Path to Solvency II, Health Care Spend & Pensio...Cook County Commissioner Bridget Gainer
 
The Impact of Increased Survival in the Assessment of Interventions for Cancer
The Impact of Increased Survival in the Assessment of Interventions for CancerThe Impact of Increased Survival in the Assessment of Interventions for Cancer
The Impact of Increased Survival in the Assessment of Interventions for CancerYork Health Economics Consortium (YHEC)
 
Wellness and benefits planning
Wellness and benefits planningWellness and benefits planning
Wellness and benefits planningCG Hylton Inc.
 
Income tax personal allowance for those aged under 65
Income tax personal allowance for those aged under 65Income tax personal allowance for those aged under 65
Income tax personal allowance for those aged under 65Keyconsulting UK
 
Report in ECOLRT gdp and gnp
Report in ECOLRT gdp and gnpReport in ECOLRT gdp and gnp
Report in ECOLRT gdp and gnpArvin Dela Cruz
 
Basis for beveridge 2.0
Basis for beveridge 2.0Basis for beveridge 2.0
Basis for beveridge 2.0Henry Tapper
 
Exploring the impacts of welfare reform using policy microsimulation and admi...
Exploring the impacts of welfare reform using policy microsimulation and admi...Exploring the impacts of welfare reform using policy microsimulation and admi...
Exploring the impacts of welfare reform using policy microsimulation and admi...Policy in Practice
 

Similaire à Wider_economic_impacts_of_health_treatments (20)

Vasco Da Gama 2015 Dublin The Effect of the Economic Crisis on the Irish Heal...
Vasco Da Gama 2015 Dublin The Effect of the Economic Crisis on the Irish Heal...Vasco Da Gama 2015 Dublin The Effect of the Economic Crisis on the Irish Heal...
Vasco Da Gama 2015 Dublin The Effect of the Economic Crisis on the Irish Heal...
 
Budget 2020 summary for workers and business
Budget 2020 summary for workers and businessBudget 2020 summary for workers and business
Budget 2020 summary for workers and business
 
Richard_Dasher_Healing the Economy_Estimating the Economic Impact of India’s ...
Richard_Dasher_Healing the Economy_Estimating the Economic Impact of India’s ...Richard_Dasher_Healing the Economy_Estimating the Economic Impact of India’s ...
Richard_Dasher_Healing the Economy_Estimating the Economic Impact of India’s ...
 
John Appleby on improving NHS productivity
John Appleby on improving NHS productivityJohn Appleby on improving NHS productivity
John Appleby on improving NHS productivity
 
Stephen Aldridge -Public sector efficiency in the UK
Stephen Aldridge -Public sector efficiency in the UKStephen Aldridge -Public sector efficiency in the UK
Stephen Aldridge -Public sector efficiency in the UK
 
Earnings-related benefits in Ireland: Rationale, costs and work incentives
 Earnings-related benefits in Ireland: Rationale, costs and work incentives Earnings-related benefits in Ireland: Rationale, costs and work incentives
Earnings-related benefits in Ireland: Rationale, costs and work incentives
 
Understanding Integrated Care in England
Understanding Integrated Care in EnglandUnderstanding Integrated Care in England
Understanding Integrated Care in England
 
Estimating the Budgetary Implications of Prevention Policies
Estimating the Budgetary Implications of Prevention PoliciesEstimating the Budgetary Implications of Prevention Policies
Estimating the Budgetary Implications of Prevention Policies
 
Chapter 2
Chapter 2Chapter 2
Chapter 2
 
Slides NERI Seminar - PGK & TH - 12 Sept 18
Slides NERI Seminar - PGK & TH - 12 Sept 18Slides NERI Seminar - PGK & TH - 12 Sept 18
Slides NERI Seminar - PGK & TH - 12 Sept 18
 
Assessing Effects on the Federal Budget of Policies to Promote Health and Pre...
Assessing Effects on the Federal Budget of Policies to Promote Health and Pre...Assessing Effects on the Federal Budget of Policies to Promote Health and Pre...
Assessing Effects on the Federal Budget of Policies to Promote Health and Pre...
 
Commissioner Bridget Gainer - Path to Solvency II, Health Care Spend & Pensio...
Commissioner Bridget Gainer - Path to Solvency II, Health Care Spend & Pensio...Commissioner Bridget Gainer - Path to Solvency II, Health Care Spend & Pensio...
Commissioner Bridget Gainer - Path to Solvency II, Health Care Spend & Pensio...
 
The Impact of Increased Survival in the Assessment of Interventions for Cancer
The Impact of Increased Survival in the Assessment of Interventions for CancerThe Impact of Increased Survival in the Assessment of Interventions for Cancer
The Impact of Increased Survival in the Assessment of Interventions for Cancer
 
Wellness and benefits planning
Wellness and benefits planningWellness and benefits planning
Wellness and benefits planning
 
Dinámica del Gasto en Salud
Dinámica del Gasto en SaludDinámica del Gasto en Salud
Dinámica del Gasto en Salud
 
Income tax personal allowance for those aged under 65
Income tax personal allowance for those aged under 65Income tax personal allowance for those aged under 65
Income tax personal allowance for those aged under 65
 
Sp+ power point presentation white
Sp+ power point presentation whiteSp+ power point presentation white
Sp+ power point presentation white
 
Report in ECOLRT gdp and gnp
Report in ECOLRT gdp and gnpReport in ECOLRT gdp and gnp
Report in ECOLRT gdp and gnp
 
Basis for beveridge 2.0
Basis for beveridge 2.0Basis for beveridge 2.0
Basis for beveridge 2.0
 
Exploring the impacts of welfare reform using policy microsimulation and admi...
Exploring the impacts of welfare reform using policy microsimulation and admi...Exploring the impacts of welfare reform using policy microsimulation and admi...
Exploring the impacts of welfare reform using policy microsimulation and admi...
 

Plus de Office of Health Economics

OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOffice of Health Economics
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowseOffice of Health Economics
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isOffice of Health Economics
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Office of Health Economics
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?Office of Health Economics
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleOffice of Health Economics
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeOffice of Health Economics
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMROffice of Health Economics
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Office of Health Economics
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandOffice of Health Economics
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Office of Health Economics
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...Office of Health Economics
 

Plus de Office of Health Economics (20)

Annual lecture
Annual lecture Annual lecture
Annual lecture
 
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
 
Towse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne finalTowse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne final
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
 
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
 

Dernier

Work Remotely with Confluence ACE 2.pptx
Work Remotely with Confluence ACE 2.pptxWork Remotely with Confluence ACE 2.pptx
Work Remotely with Confluence ACE 2.pptxmavinoikein
 
Simulation-based Testing of Unmanned Aerial Vehicles with Aerialist
Simulation-based Testing of Unmanned Aerial Vehicles with AerialistSimulation-based Testing of Unmanned Aerial Vehicles with Aerialist
Simulation-based Testing of Unmanned Aerial Vehicles with AerialistSebastiano Panichella
 
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATIONRACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATIONRachelAnnTenibroAmaz
 
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRRINDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRRsarwankumar4524
 
Gaps, Issues and Challenges in the Implementation of Mother Tongue Based-Mult...
Gaps, Issues and Challenges in the Implementation of Mother Tongue Based-Mult...Gaps, Issues and Challenges in the Implementation of Mother Tongue Based-Mult...
Gaps, Issues and Challenges in the Implementation of Mother Tongue Based-Mult...marjmae69
 
Genshin Impact PPT Template by EaTemp.pptx
Genshin Impact PPT Template by EaTemp.pptxGenshin Impact PPT Template by EaTemp.pptx
Genshin Impact PPT Template by EaTemp.pptxJohnree4
 
Early Modern Spain. All about this period
Early Modern Spain. All about this periodEarly Modern Spain. All about this period
Early Modern Spain. All about this periodSaraIsabelJimenez
 
Anne Frank A Beacon of Hope amidst darkness ppt.pptx
Anne Frank A Beacon of Hope amidst darkness ppt.pptxAnne Frank A Beacon of Hope amidst darkness ppt.pptx
Anne Frank A Beacon of Hope amidst darkness ppt.pptxnoorehahmad
 
SBFT Tool Competition 2024 -- Python Test Case Generation Track
SBFT Tool Competition 2024 -- Python Test Case Generation TrackSBFT Tool Competition 2024 -- Python Test Case Generation Track
SBFT Tool Competition 2024 -- Python Test Case Generation TrackSebastiano Panichella
 
miladyskindiseases-200705210221 2.!!pptx
miladyskindiseases-200705210221 2.!!pptxmiladyskindiseases-200705210221 2.!!pptx
miladyskindiseases-200705210221 2.!!pptxCarrieButtitta
 
Quality by design.. ppt for RA (1ST SEM
Quality by design.. ppt for  RA (1ST SEMQuality by design.. ppt for  RA (1ST SEM
Quality by design.. ppt for RA (1ST SEMCharmi13
 
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...漢銘 謝
 
Mathan flower ppt.pptx slide orchids ✨🌸
Mathan flower ppt.pptx slide orchids ✨🌸Mathan flower ppt.pptx slide orchids ✨🌸
Mathan flower ppt.pptx slide orchids ✨🌸mathanramanathan2005
 
The 3rd Intl. Workshop on NL-based Software Engineering
The 3rd Intl. Workshop on NL-based Software EngineeringThe 3rd Intl. Workshop on NL-based Software Engineering
The 3rd Intl. Workshop on NL-based Software EngineeringSebastiano Panichella
 
Dutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
Dutch Power - 26 maart 2024 - Henk Kras - Circular PlasticsDutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
Dutch Power - 26 maart 2024 - Henk Kras - Circular PlasticsDutch Power
 
Presentation for the Strategic Dialogue on the Future of Agriculture, Brussel...
Presentation for the Strategic Dialogue on the Future of Agriculture, Brussel...Presentation for the Strategic Dialogue on the Future of Agriculture, Brussel...
Presentation for the Strategic Dialogue on the Future of Agriculture, Brussel...Krijn Poppe
 
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.comSaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.comsaastr
 
PHYSICS PROJECT BY MSC - NANOTECHNOLOGY
PHYSICS PROJECT BY MSC  - NANOTECHNOLOGYPHYSICS PROJECT BY MSC  - NANOTECHNOLOGY
PHYSICS PROJECT BY MSC - NANOTECHNOLOGYpruthirajnayak525
 
Event 4 Introduction to Open Source.pptx
Event 4 Introduction to Open Source.pptxEvent 4 Introduction to Open Source.pptx
Event 4 Introduction to Open Source.pptxaryanv1753
 
The Ten Facts About People With Autism Presentation
The Ten Facts About People With Autism PresentationThe Ten Facts About People With Autism Presentation
The Ten Facts About People With Autism PresentationNathan Young
 

Dernier (20)

Work Remotely with Confluence ACE 2.pptx
Work Remotely with Confluence ACE 2.pptxWork Remotely with Confluence ACE 2.pptx
Work Remotely with Confluence ACE 2.pptx
 
Simulation-based Testing of Unmanned Aerial Vehicles with Aerialist
Simulation-based Testing of Unmanned Aerial Vehicles with AerialistSimulation-based Testing of Unmanned Aerial Vehicles with Aerialist
Simulation-based Testing of Unmanned Aerial Vehicles with Aerialist
 
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATIONRACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
 
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRRINDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
 
Gaps, Issues and Challenges in the Implementation of Mother Tongue Based-Mult...
Gaps, Issues and Challenges in the Implementation of Mother Tongue Based-Mult...Gaps, Issues and Challenges in the Implementation of Mother Tongue Based-Mult...
Gaps, Issues and Challenges in the Implementation of Mother Tongue Based-Mult...
 
Genshin Impact PPT Template by EaTemp.pptx
Genshin Impact PPT Template by EaTemp.pptxGenshin Impact PPT Template by EaTemp.pptx
Genshin Impact PPT Template by EaTemp.pptx
 
Early Modern Spain. All about this period
Early Modern Spain. All about this periodEarly Modern Spain. All about this period
Early Modern Spain. All about this period
 
Anne Frank A Beacon of Hope amidst darkness ppt.pptx
Anne Frank A Beacon of Hope amidst darkness ppt.pptxAnne Frank A Beacon of Hope amidst darkness ppt.pptx
Anne Frank A Beacon of Hope amidst darkness ppt.pptx
 
SBFT Tool Competition 2024 -- Python Test Case Generation Track
SBFT Tool Competition 2024 -- Python Test Case Generation TrackSBFT Tool Competition 2024 -- Python Test Case Generation Track
SBFT Tool Competition 2024 -- Python Test Case Generation Track
 
miladyskindiseases-200705210221 2.!!pptx
miladyskindiseases-200705210221 2.!!pptxmiladyskindiseases-200705210221 2.!!pptx
miladyskindiseases-200705210221 2.!!pptx
 
Quality by design.. ppt for RA (1ST SEM
Quality by design.. ppt for  RA (1ST SEMQuality by design.. ppt for  RA (1ST SEM
Quality by design.. ppt for RA (1ST SEM
 
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
 
Mathan flower ppt.pptx slide orchids ✨🌸
Mathan flower ppt.pptx slide orchids ✨🌸Mathan flower ppt.pptx slide orchids ✨🌸
Mathan flower ppt.pptx slide orchids ✨🌸
 
The 3rd Intl. Workshop on NL-based Software Engineering
The 3rd Intl. Workshop on NL-based Software EngineeringThe 3rd Intl. Workshop on NL-based Software Engineering
The 3rd Intl. Workshop on NL-based Software Engineering
 
Dutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
Dutch Power - 26 maart 2024 - Henk Kras - Circular PlasticsDutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
Dutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
 
Presentation for the Strategic Dialogue on the Future of Agriculture, Brussel...
Presentation for the Strategic Dialogue on the Future of Agriculture, Brussel...Presentation for the Strategic Dialogue on the Future of Agriculture, Brussel...
Presentation for the Strategic Dialogue on the Future of Agriculture, Brussel...
 
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.comSaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
 
PHYSICS PROJECT BY MSC - NANOTECHNOLOGY
PHYSICS PROJECT BY MSC  - NANOTECHNOLOGYPHYSICS PROJECT BY MSC  - NANOTECHNOLOGY
PHYSICS PROJECT BY MSC - NANOTECHNOLOGY
 
Event 4 Introduction to Open Source.pptx
Event 4 Introduction to Open Source.pptxEvent 4 Introduction to Open Source.pptx
Event 4 Introduction to Open Source.pptx
 
The Ten Facts About People With Autism Presentation
The Ten Facts About People With Autism PresentationThe Ten Facts About People With Autism Presentation
The Ten Facts About People With Autism Presentation
 

Wider_economic_impacts_of_health_treatments

  • 1. Methodology for estimating the wider economic impacts of health treatments 1. Changes in patient health have wider economic consequences 2. Patients’ wider economic impact: production net of consumption 3. Estimating net production as a function of patient health 4. Results – single patient net production rates (given health state) Patient Age: 64 Gen: M (ICD: QoL: G) 60% Net production £500 pcm Calculation Mechanism 5. Results – treatment impacts (by ICD, and for marginal NHS £)
  • 2. Methodology for estimating the wider economic impacts of health treatments 1. Changes in patient health have wider economic consequences 2. Patients’ wider economic impact: production net of consumption 3. Estimating net production as a function of patient health 4. Results – single patient net production rates (given health state) Patient Age: 64 Gen: M (ICD: QoL: G) 60% Net production £500 pcm Calculation Mechanism 5. Results – treatment impacts (by ICD, and for marginal NHS £)
  • 3. Measuring the economic impact of health using net production Health (and treatments) have impacts beyond the patient Health (QALYs) Work more? Pay more tax? Need less benefits? Costs (£) Need less social care? Need less care by family? Economic impact on society (i.e. other people) Contribute to family finances? Look after others? +
  • 4. 1. Changes in patient health have wider economic consequences 2. Patients’ wider economic impact: production net of consumption 3. Estimating net production as a function of patient health 4. Results – single patient net production rates (given health state) Patient Age: 64 Gen: M (ICD: QoL: G) 60% Net production £500 pcm Calculation Mechanism 5. Results – treatment impacts (by ICD, and for marginal NHS £) Methodology for estimating the wider economic impacts of health treatments
  • 5. Patient Effect on others Family and friends Other members of society Gross production, or contribution of resources (+) Gross consumption, or utilisation of resources (-) Net production +£500pcm +£1,500 pcm -£1,000 pcm Costs, eg spending on nursing home Family income Domestic work Need for informal care by family Govt costs, eg welfare, social care Govt tax revenues Volunteer work Any excess production (consumption) by patient means a benefit (cost) to someone else =£500 pcm Defining production and consumption effects Net production = consumption for others
  • 6. Defining production and consumption effects Net production = consumption for others Patient Family and friends Other members of society Gross production, or contribution of resources (+) Gross consumption, or utilisation of resources (-) +£1,500 pcm -£1,000 pcm Costs, eg spending on nursing home Family income Domestic work Need for informal care by family Govt costs, eg welfare, social care Govt tax revenues Volunteer work Any excess production (consumption) by patient means a benefit (cost) to someone else =£500 pcm Net production +£500pcm
  • 7. 1. Changes in patient health have wider economic consequences 2. Patients’ wider economic impact: production net of consumption 3. Estimating net production as a function of patient health 4. Results – single patient net production rates (given health state) Patient Age: 64 Gen: M (ICD: QoL: G) 60% Net production £500 pcm Calculation Mechanism 5. Results – treatment impacts (by ICD, and for marginal NHS £) Methodology for estimating the wider economic impacts of health treatments
  • 8. Illustrative figures, pcm Gross production:  paid labour  unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons.  government services Patient Net production £1,500 = £500 pcm £1,000 Age: 64 Gen: M ICD: QoL: G 60% - £1,000 £1,500 International Classification of Disease (Chapter-level) £600 £900 £80 £70 £420 £300 £130 Estimating production and consumption effects Mechanism estimates production / cons as a function of health
  • 9. Illustrative figures, pcm Gross production:  paid labour  unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons.  government services Patient Net production £1,500 = £500 pcm £1,000 Age: 64 Gen: M ICD: QoL: G 60% - £1,000 £1,500 £600 £900 £80 £70 £420 £300 £130 Estimating production and consumption effects Compare to production with treatment to give impact
  • 10.  paid labour  unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons.  government services Patient Net production £1,500 = £500 pcm £1,000 Age: 64 Gen: M ICD: QoL: G 60% - £1,000 £1,500 £1,600 = £700 pcm £900 80% - £900 £1,600 Raising this patient’s QoL from 60% to 80% generates £200pcm in net production Treatment improves QoL by 20% £600 £900 £80 £70 £420 £300 £130 £950 £30 £20 £420 £300 £130 Gross production: £650 Estimating production and consumption effects Compare to production with treatment to give impact Illustrative figures, pcm
  • 11. Estimating production and consumption effects Estimating elements as functions of AGIQ – eg paid labour  paid labour Patient Age: 64 Gen: M ICD: QoL: G 80%  unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons.  government services Net production £1,500 = £500 pcm £1,000 - £1,000 £1,500 £1,600 = £700 pcm £900 - £900 £1,600 £900 £80 £70 £420 £300 £130 £950 £30 £20 £420 £300 £130 Gross production: Illustrative figures, pcm£650
  • 12. Estimating production and consumption effects Estimating elements as functions of AGIQ – eg paid labour  paid labour Patient Age: 64 Gen: M ICD: QoL: G 80% £650 Understanding Society • “did you do paid work last week?” • SF16 health instrument • age, gender etc ScHARR model • Map SF16 to EQ5D (QoL) • Estimate prob of doing work as f(Age, QoL) ONS wages data • Monthly wage, by Age, Gender if in work -> £ paid labour pcm = f (Age, Gender, QoL) +
  • 13. Estimating production and consumption effects Main current data sources Paid labour Unpaid labour Formal care Informal care Personal paid consumption Personal unpaid consumption Government services AGQ AGQ A(I)Q AGIQ A (const) A Element Dependent variables Main data sources Annual Survey of Hours and Earnings (AG) Understanding Society (AQ) Time Use Survey (AG) Sick rate, derived from Understanding Soc. (Q) Adult Soc. Care Survey, GP Patient Survey, PSSRU data HoDAR Living Costs and Food Survey Time Use Survey Public Expenditure Statistical Analysis
  • 14. 1. Changes in patient health have wider economic consequences 2. Patients’ wider economic impact: production net of consumption 3. Estimating net production as a function of patient health 4. Results – single patient net production rates (given health state) Patient Age: 64 Gen: M (ICD: QoL: G) 60% Net production £500 pcm Calculation Mechanism 5. Results – treatment impacts (by ICD, and for marginal NHS £) Methodology for estimating the wider economic impacts of health treatments
  • 15. Results – paid production £pcm paid production as a function of age and QoL NB this is the rate in a given state – not a treatment impact QoL -500 0 500 1,000 1,500 2,000 2,500 10 20 30 40 50 60 70 80 90 100 Age 0 0.2 0.5 0.7 0.9 1.0 paid labour  unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons.  government services Patient Net production (or consumption) Age: 64 Gen: M ICD: QoL: G 60%80% Gross production:
  • 16. Results – unpaid production £pcm as a function of age and QoL QoL NB this is the rate in a given state – not a treatment impact 0 500 1,000 1,500 2,000 2,500 10 20 30 40 50 60 70 80 90 100 Age 0 0.2 0.5 0.7 0.9 1.0  paid labour unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons.  government services Patient Net production (or consumption) Age: 64 Gen: M ICD: QoL: G 60%80% Gross production:
  • 17. Results – unpaid production – general unpaid labour Hours pcm in full health • Data from Time Use Survey • Diaries identify activity for each 10 min interval 0 50 100 150 200 250 300 350 0 10 20 30 40 50 60 70 80 90 100 Age M - obs F - obs M -pred F - pred • ~3000 activities classified according to whether represent unpaid labour  paid labour unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons.  government services Patient Net production (or consumption) Age: 64 Gen: M ICD: QoL: G 60%80% Gross production:
  • 18. Results – informal care consumption £pcm as a function of age and QoL QoL NB this is the rate in a given state – not a treatment impact 0 500 1,000 1,500 2,000 2,500 10 20 30 40 50 60 70 80 90 100 Age 0 0.2 0.5 0.7 0.9 1.0  paid labour  unpaid labour Gross consumption:  formal care informal care  personal paid cons.  personal unpaid cons.  government services Patient Net production (or consumption) Age: 64 Gen: M ICD: QoL: G 60%80% Gross production:
  • 19. Results – formal care consumption £pcm as a function of age and QoL QoL NB this is the rate in a given state – not a treatment impact  paid labour  unpaid labour Gross consumption: formal care  informal care  personal paid cons.  personal unpaid cons.  government services Patient Net production (or consumption) Age: 64 Gen: M ICD: QoL: G 60%80% Gross production:
  • 20. Results – private paid consumption £pcm as a function of age and QoL QoL NB this is the rate in a given state – not a treatment impact 0 200 400 600 800 1,000 1,200 1,400 10 20 30 40 50 60 70 80 90 100 Age 0 0.2 0.5 0.7 0.9 1.0  paid labour  unpaid labour Gross consumption:  formal care  informal care personal paid cons.  personal unpaid cons.  government services Patient Net production (or consumption) Age: 64 Gen: M ICD: QoL: G 60%80% Gross production:
  • 21. Results – private unpaid consumption £pcm as a function of age and QoL QoL NB this is the rate in a given state – not a treatment impact  paid labour  unpaid labour Gross consumption:  formal care  informal care  personal paid cons. personal unpaid cons.  government services Patient Net production (or consumption) Age: 64 Gen: M ICD: QoL: G 60%80% Gross production:
  • 22. Results – Government consumption £pcm as a function of age and QoL QoL NB this is the rate in a given state – not a treatment impact 0 100 200 300 400 500 600 10 20 30 40 50 60 70 80 90 100 Age 0 0.2 0.5 0.7 0.9 1.0  paid labour  unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons. government services Patient Net production (or consumption) Age: 64 Gen: M ICD: QoL: G 60%80% Gross production:
  • 23. Results – TOTAL NET PRODUCTION £pcm as a function of age and QoL QoL NB this is the rate in a given state – not a treatment impact -5,000 -4,000 -3,000 -2,000 -1,000 0 1,000 2,000 10 20 30 40 50 60 70 80 90 100 Age 0 0.2 0.5 0.7 0.9 1.0  paid labour Patient Age: 64 Gen: M ICD: QoL: G 80%  unpaid labour Gross consumption:  formal care  informal care  personal paid cons.  personal unpaid cons.  government services Net production (or consumption) Gross production:
  • 24. 1. Changes in patient health have wider economic consequences 2. Patients’ wider economic impact: production net of consumption 3. Estimating net production as a function of patient health 4. Results – single patient net production rates (given health state) Patient Age: 64 Gen: M (ICD: QoL: G) 60% Net production £500 pcm Calculation Mechanism 5. Results – treatment impacts (by ICD, and for marginal NHS £) Methodology for estimating the wider economic impacts of health treatments
  • 25. Calculating net production effects of health treatments Principle: aggregate over time, like QoL (for QALYs) QoL Net prod (pa) QALY gain £1,000 + £2,000 1 2 Time, yrs 0.5 1.0 = 1.5 QALY untreated treated 1 2 Time, yrs £2,000 untreated treated £1,000 = £3,000 0.5 + 1 Net production impact In principle straightforward – map directly from QoL
  • 26. Calculating net production effects of health treatments Practical problem: net production non-linear, esp. over age -5,000 -4,000 -3,000 -2,000 -1,000 0 1,000 2,000 10 20 30 40 50 60 70 80 90 100 Age 0 0.2 0.5 0.7 0.9 1.0 • Cannot use average patient ages • Need to calculate across actual ages for affected population.. • ..or use reference estimates representing population age distribution
  • 27. Reference Estimates (1281 ICDs) ICD -eg M06: Rheumatoid Arthritis For each ICD: distrib. of patients (16 AG bins) = £37,745 per QALY gained £ net production + enough data for each bin to calculate all elements of net production 0% 5% 10% 15% 20% 25% 30% 35% 40% 0-4 5-14 15-29 30-44 45-59 60-69 70-79 80+ Patient population distribution F M Age bins Calculating net production effects of health treatments One solution: use reference estimates = £2.52 per £NHS* * Assuming £15,000 marginal cost / QALY
  • 28. Production and consumption effects of health treatments M06 Rheumatoid arthritis: results by category, and key inputs 0% 5% 10% 15% 20% 25% 30% 35% 40% 0-4 5-14 15-29 30-44 45-59 60-69 70-79 80+ Patient population distribution F M 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0-4 5-14 15-29 30-44 45-59 60-69 70-79 80+ Distribution of QALY gain by QoL vs LoL QoL LoL Total QoL gains LoL gains Total production, £ 26,849 25,691 1,158 Paid production, £ 11,276 11,008 268 Unpaid production, £ 15,573 14,683 890 Total consumption, £ -10,896 -14,601 3,705 Formal care, £ -1,765 -2,293 528 Informal care, £ -13,157 -13,509 352 Private paid consumption, £ 1,492 489 1,003 Private unpaid consumption, £ 1,946 712 1,234 (Childcare consumption), £ 0 0 0 Govt consumption, £ 588 0 588 Net production (prod - cons), £ 37,745 40,292 -2,547
  • 29. Production and consumption effects of health treatments M06 Rheumatoid arthritis: paid labour impact
  • 30. Production and consumption effects of health treatments M06 Rheumatoid arthritis: informal care impact 0 2 4 6 8 10 12 14 0-4 5-14 15-29 30-44 45-59 60-69 70-79 80+ Ave Informal care need pp, days pcm Untreated Treated
  • 31. Results: net production impact of NHS treatments Net production impact in select conditions Code Disease £NP / QALY £NP / £NHS F03 Dementia 40,068 2.67 M05 Rheumatoid arthritis 37,745 2.52 E11 Diabetes 30,969 2.06 M81 Osteoporosis 23,483 1.57 F30 Depression 22,826 1.52 F20 Schizophrenia 19,625 1.31 G20 Parkinson's disease 16,950 1.13 J45 Asthma 16,267 1.08 G40 Epilepsy 16,031 1.07 displ (average displaced QALY) 13,925 0.93 C53 Cervical cancer 11,248 0.75 E66 Obesity 8,524 0.57 C50 Breast cancer 8,072 0.54 I64 Stroke -1,350 -0.09 C18 Colon cancer -2,262 -0.15 I21 Acute myocardial infarction -8,223 -0.55 I26 Embolisms, fibrillation, thrombosis -10,705 -0.71 J10 Influenza -14,982 -1.00 C22 Liver cancer -25,867 -1.72 C34 Lung cancer -29,135 -1.94 C25 Pancreatic cancer -46,141 -3.08
  • 32. Results: net production impact of NHS treatments Description of NHS activity at the margin 16 A/G groups F 0-5 F 6-15 F 16-30 F 31-45 F 46-59 F 60-69 F 70-79 F 80+ M 0-5 M 6-15 M 16-30 M 31-45 M 46-59 M 60-69 M 70-79 M 80+ F 0-5 Net prod. / £ -1.27 -1.32 -0.51 1.20 0.55 -0.85 -1.59 -2.31 -1.43 -1.52 -0.59 1.52 0.76 -0.90 -1.63 -2.18 -0.13 0.09 0.72 1.70 1.61 0.24 0.04 -0.01 -0.27 -0.12 0.32 1.83 1.51 -0.08 -0.41 -0.55 -0.15 £1 NHS (margin) F 0-5 F 6-15 F 16-30 F 31-45 F 46-59 F 60-69 F 70-79 F 80+ M 0-5 M 6-15 M 16-30 M 31-45 M 46-59 M 60-69 M 70-79 M 80+ £ Net Prod (margin) 1,281 conditions Abnormal blood-pressure reading, without diagnosis Abnormal findings in cerebrospinal fluid Abnormal findings in specimens from digestive organs & abdominal cavity Abnormal findings in specimens from male genital organs Abnormal findings in specimens from other organs, systems and tissues Abnormal findings in specimens from respiratory organs and thorax Abnormal findings on antenatal screening of mother Abnormal findings on diagnostic imaging of breast Abnormal findings on diagnostic imaging of central nervous system Abnormal findings on diagnostic imaging of lung Abnormal findings on diagnostic imaging of other body structures Abnormal involuntary movements Abnormal results of function studies Abnormal serum enzyme levels Abnormalities of breathing Abnormalities of forces of labour Abnormalities of gait and mobility Abnormalities of heart beat Abnormality of red blood cells Abnormality of white blood cells, not elsewhere classified … Venous complications in pregnancy Venous complications in the puerperium Ventral hernia Viral agents as the cause of disease classified to other chapters Viral and other specified intestinal infections Viral conjunctivitis Viral infection of unspecified site Viral meningitis Viral pneumonia, not elsewhere classified Viral warts Visual disturbances Vitamin A deficiency Vitamin B12 deficiency anaemia Vitamin D deficiency Vitiligo Voice disturbances Volume depletion Whooping cough Yaws Zoster [herpes zoster] Zygomycosis
  • 33. Results: net production impact of NHS treatments Net production impact marginal £ spent in NHS Net production, £ 0.93 Production, £ 1.51 Paid production, £ 0.63 Unpaid production, £ 0.89 Consumption, £ 0.59 Formal care consumption, £ -0.02 Informal care consumption, £ -0.17 Private paid consumption, £ 0.29 Private unpaid consumption, £ 0.34 Childcare consumption, £ 0.00 Government consumption, £ 0.14 Direct GDP impact Impact on informal carers Total economic value Total production impact £1 NHS (margin) NB this is additional to value of health itself
  • 34. 1. Changes in patient health have wider economic consequences 2. Patients’ wider economic impact: production net of consumption 3. Estimating net production as a function of patient health 4. Results – single patient net production rates (given health state) Patient Age: 64 Gen: M (ICD: QoL: G) 60% Net production £500 pcm Calculation Mechanism 5. Results – treatment impacts (by ICD, and for marginal NHS £) Methodology for estimating the wider economic impacts of health treatments